Jacobio Pharma Unveils Promising BET Inhibitor Data for Treating Myelofibrosis at 2024 ASH Annual Meeting
Jacobio Pharma, a clinical-stage oncology company, recently made waves in the medical community with the presentation of preliminary Phase I data for its innovative BET inhibitor, JAB-8263, which is being developed for the treatment of myelofibrosis (MF). This announcement took place at the 2024 Annual Meeting of the American Society of Hematology (ASH) held in San Diego, California, highlighting the ongoing advancements in therapies targeting so-called undruggable diseases.
The results from the trial were met with optimism as JAB-8263 demonstrated a promising safety profile, with a Recommended Phase 2 Dose (RP2D) established at 0.3mg taken once a day. Preliminary efficacy data also indicated that the majority of patients treated with JAB-8263 experienced significant health improvements—showing a reduction in spleen volume and an overall decrease in total symptom scores.
As of October 17, 2024, 16 patients diagnosed with intermediate to high-risk MF were enrolled in the study, and an encouraging number of these patients underwent at least one post-treatment efficacy evaluation. Notably, all patients that completed the assessment displayed a mean spleen volume reduction of 19.95% at the 24-week mark, while the best responses to treatment yielded an impressive 26.16% reduction in spleen volume.
Further breaks down of results revealed that 2 out of the 16 participants achieved a spleen volume reduction of 35% or more. 60% of the evaluated patients also reported a reduction of 50% or more in their total symptom score by week 24. Among those receiving prior treatment with JAK inhibitors, significant symptom improvements were noted, indicating that JAB-8263 may hold considerable potential even for patients with a history of other therapeutic interventions.
Dr. Andrea Wang-Gillam, Chief Medical Officer and Global Head of Research and Development at Jacobio, expressed her excitement regarding these preliminary findings. She stated, "The initial data reflects the encouraging therapeutic potential of our potent BET inhibitor in combating myelofibrosis. We look forward to exploring a broader scope of indications for JAB-8263, as we aim to provide hope to a larger number of cancer patients." This forward-thinking approach aligns with Jacobio's commitment to expanding its research and development on innovative oncology therapies.
Furthermore, Jacobio Pharma is geared towards establishing itself as a leader in the oncology field with its focus on developing drugs targeting complex molecular mechanisms across various signaling pathways. Their ambitious pipeline includes ongoing projects in crucial areas such as KRAS mutations, immune checkpoint inhibitors, and tumor metabolism.
The ongoing study’s positive implications are not limited to myelofibrosis; the company is also actively pursuing the potential of JAB-8263 in treating solid tumors, expanding their investigational landscape as they strive to minimize suffering and improve outcomes for cancer patients worldwide. Jacobio's research and development centers in Beijing, Shanghai, and Boston are strategically positioned to facilitate these efforts, supported by their advanced drug discovery platforms.
As Jacobio continues its commitment to innovation in the realm of oncology, the medical community and patients alike remain hopeful for the promising developments that the BET inhibitor, JAB-8263, may bring in the future. By driving forward with determination towards broader applications and deeper research into the cancer landscape, Jacobio Pharma stands at the forefront of a vital battle against undruggable cancer targets.
The results from the trial were met with optimism as JAB-8263 demonstrated a promising safety profile, with a Recommended Phase 2 Dose (RP2D) established at 0.3mg taken once a day. Preliminary efficacy data also indicated that the majority of patients treated with JAB-8263 experienced significant health improvements—showing a reduction in spleen volume and an overall decrease in total symptom scores.
As of October 17, 2024, 16 patients diagnosed with intermediate to high-risk MF were enrolled in the study, and an encouraging number of these patients underwent at least one post-treatment efficacy evaluation. Notably, all patients that completed the assessment displayed a mean spleen volume reduction of 19.95% at the 24-week mark, while the best responses to treatment yielded an impressive 26.16% reduction in spleen volume.
Further breaks down of results revealed that 2 out of the 16 participants achieved a spleen volume reduction of 35% or more. 60% of the evaluated patients also reported a reduction of 50% or more in their total symptom score by week 24. Among those receiving prior treatment with JAK inhibitors, significant symptom improvements were noted, indicating that JAB-8263 may hold considerable potential even for patients with a history of other therapeutic interventions.
Dr. Andrea Wang-Gillam, Chief Medical Officer and Global Head of Research and Development at Jacobio, expressed her excitement regarding these preliminary findings. She stated, "The initial data reflects the encouraging therapeutic potential of our potent BET inhibitor in combating myelofibrosis. We look forward to exploring a broader scope of indications for JAB-8263, as we aim to provide hope to a larger number of cancer patients." This forward-thinking approach aligns with Jacobio's commitment to expanding its research and development on innovative oncology therapies.
Furthermore, Jacobio Pharma is geared towards establishing itself as a leader in the oncology field with its focus on developing drugs targeting complex molecular mechanisms across various signaling pathways. Their ambitious pipeline includes ongoing projects in crucial areas such as KRAS mutations, immune checkpoint inhibitors, and tumor metabolism.
The ongoing study’s positive implications are not limited to myelofibrosis; the company is also actively pursuing the potential of JAB-8263 in treating solid tumors, expanding their investigational landscape as they strive to minimize suffering and improve outcomes for cancer patients worldwide. Jacobio's research and development centers in Beijing, Shanghai, and Boston are strategically positioned to facilitate these efforts, supported by their advanced drug discovery platforms.
As Jacobio continues its commitment to innovation in the realm of oncology, the medical community and patients alike remain hopeful for the promising developments that the BET inhibitor, JAB-8263, may bring in the future. By driving forward with determination towards broader applications and deeper research into the cancer landscape, Jacobio Pharma stands at the forefront of a vital battle against undruggable cancer targets.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.